JP2013531679A - 抗体製剤 - Google Patents

抗体製剤 Download PDF

Info

Publication number
JP2013531679A
JP2013531679A JP2013518765A JP2013518765A JP2013531679A JP 2013531679 A JP2013531679 A JP 2013531679A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013531679 A JP2013531679 A JP 2013531679A
Authority
JP
Japan
Prior art keywords
antibody
formulation
antibody fragment
rsa
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531679A5 (enExample
Inventor
ディミトロヴァ，マリアーナ，エヌ．
モーディ，ニール
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2013531679A publication Critical patent/JP2013531679A/ja
Publication of JP2013531679A5 publication Critical patent/JP2013531679A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2013518765A 2010-07-02 2011-07-01 抗体製剤 Pending JP2013531679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36120910P 2010-07-02 2010-07-02
US61/361,209 2010-07-02
PCT/US2011/042838 WO2012003470A2 (en) 2010-07-02 2011-07-01 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015166305A Division JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Publications (2)

Publication Number Publication Date
JP2013531679A true JP2013531679A (ja) 2013-08-08
JP2013531679A5 JP2013531679A5 (enExample) 2014-08-14

Family

ID=45402685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013518765A Pending JP2013531679A (ja) 2010-07-02 2011-07-01 抗体製剤
JP2015166305A Pending JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015166305A Pending JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Country Status (9)

Country Link
US (1) US8754195B2 (enExample)
EP (1) EP2588141A4 (enExample)
JP (2) JP2013531679A (enExample)
CN (1) CN103108658B (enExample)
AU (2) AU2011274363A1 (enExample)
BR (1) BR112012033457A2 (enExample)
CA (1) CA2803998A1 (enExample)
SG (1) SG186421A1 (enExample)
WO (1) WO2012003470A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520206A (ja) * 2012-06-21 2015-07-16 ユセベ ファルマ ソシエテ アノニム 医薬製剤
JP2016034939A (ja) * 2014-07-31 2016-03-17 キユーピー株式会社 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
RS59880B1 (sr) * 2013-09-27 2020-03-31 Hoffmann La Roche Formulacije za anti-pdl1 antitelo
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
EP4606820A3 (en) 2015-11-30 2025-10-29 Medimmune, LLC Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
PL3389636T3 (pl) 2015-12-16 2022-11-28 Regeneron Pharmaceuticals, Inc. Kompozycje i metody wytwarzania mikrocząstek białkowych
CN105920600A (zh) * 2016-04-19 2016-09-07 上海景泽生物技术有限公司 一种稳定的抗vegf抗体制剂及其用途
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
JP2024502825A (ja) * 2020-12-30 2024-01-23 エーマックス バイオ， インコーポレイテッド 抗体の局所的延長放出

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503781A (ja) * 1996-11-19 2001-03-21 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤
JP2002504907A (ja) * 1997-06-13 2002-02-12 ジェネンテク，インコーポレイテッド 抗体製剤
JP2004532798A (ja) * 2000-10-12 2004-10-28 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
JP2008546699A (ja) * 2005-06-15 2008-12-25 シェーリング コーポレイション 抗ｉｇｆ１ｒ抗体処方物
JP2009501141A (ja) * 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
JP2009540015A (ja) * 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
JP2010505852A (ja) * 2006-10-06 2010-02-25 アムジエン・インコーポレーテツド 安定な抗体製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU629920B2 (en) 1989-02-09 1992-10-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Type oc platelet-derived growth factor receptor gene
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
IE920318A1 (en) 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
US5444151A (en) 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2003068259A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
MXPA05005925A (es) 2002-12-02 2006-02-08 Abgenix Inc Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US20080199438A1 (en) 2004-03-16 2008-08-21 Dnavec Research Inc. Methods For Suppressing Tumor Proliferation
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503781A (ja) * 1996-11-19 2001-03-21 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤
JP2002504907A (ja) * 1997-06-13 2002-02-12 ジェネンテク，インコーポレイテッド 抗体製剤
JP2004532798A (ja) * 2000-10-12 2004-10-28 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
JP2008546699A (ja) * 2005-06-15 2008-12-25 シェーリング コーポレイション 抗ｉｇｆ１ｒ抗体処方物
JP2009501141A (ja) * 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
JP2009540015A (ja) * 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
JP2010505852A (ja) * 2006-10-06 2010-02-25 アムジエン・インコーポレーテツド 安定な抗体製剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520206A (ja) * 2012-06-21 2015-07-16 ユセベ ファルマ ソシエテ アノニム 医薬製剤
JP2016034939A (ja) * 2014-07-31 2016-03-17 キユーピー株式会社 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法

Also Published As

Publication number Publication date
US8754195B2 (en) 2014-06-17
AU2011274363A1 (en) 2013-01-24
BR112012033457A2 (pt) 2017-04-04
US20120009199A1 (en) 2012-01-12
CN103108658A (zh) 2013-05-15
EP2588141A4 (en) 2014-12-03
JP2016026164A (ja) 2016-02-12
SG186421A1 (en) 2013-01-30
EP2588141A2 (en) 2013-05-08
WO2012003470A2 (en) 2012-01-05
AU2016201291A1 (en) 2016-03-17
CN103108658B (zh) 2015-08-19
CA2803998A1 (en) 2012-01-05
WO2012003470A3 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
US8754195B2 (en) Antibody formulations
ES2402380T3 (es) Agentes de unión dirigidos que se dirigen a PDGFR-alfa y usos de los mismos
US10689451B2 (en) Anti-BAFFR antibody therapeutic formulations
JP7112327B2 (ja) ベバシズマブの緩衝された製剤
JP2023109942A (ja) 単独およびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
JP2020518599A (ja) プログラム死受容体１（ｐｄ−１）抗体の安定製剤およびその使用方法
EP3191524A1 (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
CA2681743A1 (en) Stable antibody formulations
AU2006259536A1 (en) Anti-IGF1R antibody formulations
US12453781B2 (en) Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate
JP7475341B2 (ja) 抗ヒトｐｄ－１抗体結晶およびその使用方法
CA3080137A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
US20220119545A1 (en) Cdcp1-targeted therapies
JP2024543236A (ja) 抗ｖｉｓｔａ抗体及びその使用
TW202511293A (zh) 包含抗ｃｃｒ８抗體的製劑及其用途
BR112021013571A2 (pt) Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
EP4164594B1 (en) Antibody formulation diluent
CN114040754A (zh) 用于稳定液体蛋白质制剂的组合物及方法
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
WO2024098180A1 (en) Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
CN113015748B (zh) 抗人pd-1抗体晶体及其使用方法
KR20240038005A (ko) B7-h3 항체의 약학적 조성물 및 그것의 용도
JP2024538140A (ja) 抗ｏｘ４０モノクローナル抗体を含む医薬製剤
HK40060084A (en) Composition and methods for stabilizing liquid protein formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027